Jurik Mutter
A5054251528- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Glioma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer-related molecular mechanisms research
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Molecular Biology Techniques and Applications
- Single-cell and spatial transcriptomics
- Brain Metastases and Treatment
- interferon and immune responses
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- Pancreatic function and diabetes
- Cancer Cells and Metastasis
- Hepatitis C virus research
- Domain Adaptation and Few-Shot Learning
- Tuberous Sclerosis Complex Research
- Eosinophilic Disorders and Syndromes
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- Ubiquitin and proteasome pathways
- Renal and related cancers
Stanford University
2023-2025
Stratford University
2025
University of Freiburg
2020-2024
LMU Klinikum
2019-2023
Ludwig-Maximilians-Universität München
2019-2023
University Medical Center Freiburg
2021
PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably heterogeneous, yet identification at high risk for treatment failure is challenging. Furthermore, CNSL diagnosis often remains unconfirmed because contraindications invasive stereotactic biopsies. Therefore, improved biomarkers needed to better stratify into groups, predict response, and noninvasively identify CNSL. PATIENTS AND METHODS We explored the value circulating tumor DNA (ctDNA) early outcome prediction,...
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile genotypes in patients with non‐small‐cell lung cancer (NSCLC). However, little is known about its dynamics during after resection, or for predicting clinical outcomes. Here, we applied targeted‐capture high‐throughput sequencing approach ctDNA at various milestones assessed predictive value early‐stage locally advanced NSCLC. We prospectively enrolled...
We introduce LLM-Lasso, a novel framework that leverages large language models (LLMs) to guide feature selection in Lasso $\ell_1$ regression. Unlike traditional methods rely solely on numerical data, LLM-Lasso incorporates domain-specific knowledge extracted from natural language, enhanced through retrieval-augmented generation (RAG) pipeline, seamlessly integrate data-driven modeling with contextual insights. Specifically, the LLM generates penalty factors for each feature, which are...
Abstract Background: Gene expression profiling is crucial for understanding cancer dynamics and development, aiding in the identification of molecular subtypes, predicting patient outcomes, discovering therapeutic biomarkers. Traditional methods rely on invasive tissue specimens analyzed through RNA-seq or microarrays. These approaches can delay diagnosis due to scheduling challenges, pose risks complications during after surgery, may be inaccessible high-risk frail patients. Recently,...
Background and aims Besides well-defined genetic alterations, the dedifferentiation of mature acinar cells is an important prerequisite for pancreatic carcinogenesis. Acinar-specific genes controlling cell homeostasis are extensively downregulated during cancer development; however, underlying mechanisms poorly understood. Now, we devised a novel in vitro strategy to determine genome-wide dynamics epigenetic landscape Design With our carcinogenic sequence, performed global gene expression...
Central nervous system lymphomas (CNSL) display remarkable clinical heterogeneity, yet accurate prediction of outcomes remains challenging. The IPCG criteria are widely used in routine practice for the assessment treatment response. However, value ultimate outcome is largely unclear, mainly due to uncertainty delineating complete from partial responses during and after treatment.
<title>Abstract</title> Various clinical scenarios preclude or delay invasive stereotactic biopsies and subsequent histopathological assessment for the diagnosis of central nervous system lymphoma (CNSL), necessitating innovative minimal-invasive strategies. We designed a digital droplet PCR (ddPCR) assay identification CNSL in practice by detecting <italic>MYD88</italic> L265P mutations circulating tumor DNA (ctDNA) cerebrospinal fluid (CSF). After approval national accreditation authority,...
Introduction: The scarcity of malignant Reed-Sternberg cells has hampered comprehensive genomic profiling classic Hodgkin lymphoma (cHL) as might inform personalized therapeutic strategies. Since circulating tumor DNA (ctDNA) shown utility in non-Hodgkin genotyping and risk stratification, we employed a noninvasive approach cHL to overcome challenges imposed by low fractions. Methods: We profiled baseline plasma samples from 366 patients diagnosed with cHL, 99% whom were enrolled prior...
Introduction: The MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) significantly improved outcome of patients (pts) with primary CNS lymphoma (PCNSL) enrolled in the IELSG32 trial. At a median follow-up 40 months, both whole-brain irradiation (WBRT) and autologous transplantation (ASCT) resulted similar progression-free survival (PFS) rates. Sound assessment overall (OS), late complications, incidence secondary tumors, cognitive impairment require, however, longer follow-up....
Introduction: Circulating tumor DNA (ctDNA) has great potential as a noninvasive biomarker in diverse systemic lymphomas (Huet et al, J Clin Oncol 2020). Noninvasive access to tumor-derived is particularly appealing for patients with primary CNS lymphoma (PCNSL), since material otherwise requires invasive surgical procedures. Here, we explored the value of ctDNA PCNSL disease classification, MRD detection, and early prediction relapse. Methods: We applied Cancer Personalized Profiling by...